Immuneering Corp Operating Income Over Time
| IMRX Stock | USD 5.00 0.25 4.76% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Immuneering Corp Performance and Immuneering Corp Correlation. Immuneering | Build AI portfolio with Immuneering Stock |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immuneering Corp. Market participants price Immuneering higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Immuneering Corp assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Immuneering Corp requires distinguishing between market price and book value, where the latter reflects Immuneering's accounting equity. The concept of intrinsic value - what Immuneering Corp's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Immuneering Corp's price substantially above or below its fundamental value.
Please note, there is a significant difference between Immuneering Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immuneering Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Immuneering Corp's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Operating Income Analysis
Compare Immuneering Corp and related stocks such as Foghorn Therapeutics, Pyxis Oncology, and Nautilus Biotechnology Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FHTX | (26 M) | (26 M) | (26 M) | (26 M) | (26 M) | (26 M) | (26 M) | (26 M) | (26 M) | (51.1 M) | (68.5 M) | (100.7 M) | (117.1 M) | (107.9 M) | (102.7 M) | (92.4 M) | (97 M) |
| PYXS | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (12.9 M) | (69.7 M) | (123.5 M) | (82.2 M) | (89.5 M) | (80.5 M) | (84.5 M) |
| NAUT | (111.7 M) | (111.7 M) | (111.7 M) | (111.7 M) | (111.7 M) | (111.7 M) | (111.7 M) | (111.7 M) | (111.7 M) | (10.1 M) | (15.7 M) | (50.5 M) | (63.6 M) | (76.2 M) | (81.5 M) | (73.3 M) | (77 M) |
| ZURA | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (27.2 M) | (62.6 M) | (55.2 M) | (49.7 M) | (52.2 M) |
| HUMA | (85.7 M) | (85.7 M) | (85.7 M) | (85.7 M) | (85.7 M) | (85.7 M) | (85.7 M) | (85.7 M) | (85.7 M) | (85.7 M) | (64.6 M) | (81.2 M) | (84.6 M) | (100 M) | (114.4 M) | (103 M) | (108.1 M) |
| ASMB | (7.2 M) | (34 M) | (24.9 M) | (19.6 M) | (24 M) | (29.7 M) | (45.3 M) | (52.2 M) | (92.7 M) | (102.7 M) | (64.8 M) | (132.7 M) | (94.1 M) | (64.6 M) | (45.4 M) | (40.9 M) | (42.9 M) |
| ENTA | 6.9 M | 21.3 M | 9 M | 19 M | 124.1 M | 30.8 M | 24.6 M | 88.3 M | 36.7 M | (41.6 M) | (109.6 M) | (123.8 M) | (137.2 M) | (121.7 M) | (85.3 M) | (76.8 M) | (73 M) |
| ARCT | (3.9 M) | (3.9 M) | (1.5 M) | (10.3 M) | (33.1 M) | (19.7 M) | (25.2 M) | (10.5 M) | (21.8 M) | (25.5 M) | (71.5 M) | (202.9 M) | 12.2 M | (78.2 M) | (95.7 M) | (86.1 M) | (81.8 M) |
| TNYA | (27.7 M) | (27.7 M) | (27.7 M) | (27.7 M) | (27.7 M) | (27.7 M) | (27.7 M) | (27.7 M) | (27.7 M) | (27.7 M) | (38.9 M) | (72.8 M) | (125.6 M) | (131.2 M) | (115.9 M) | (104.4 M) | (109.6 M) |
| TRDA | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (26.7 M) | (51.1 M) | (97.2 M) | (3.2 M) | 47 M | 54.1 M | 56.8 M |
Immuneering Corp and related stocks such as Foghorn Therapeutics, Pyxis Oncology, and Nautilus Biotechnology Operating Income description
Operating Income is the amount of profit realized from Immuneering Corp operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Immuneering Corp is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Immuneering Corp | IMRX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 245 Main Street, |
| Exchange | NASDAQ Exchange |
USD 5.0
Additional Tools for Immuneering Stock Analysis
When running Immuneering Corp's price analysis, check to measure Immuneering Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immuneering Corp is operating at the current time. Most of Immuneering Corp's value examination focuses on studying past and present price action to predict the probability of Immuneering Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immuneering Corp's price. Additionally, you may evaluate how the addition of Immuneering Corp to your portfolios can decrease your overall portfolio volatility.